Synergy Empire Ltd — Form 8-K/A
Filed July 6, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 72/100
What the filing says
On July 29, 2024, Synergy Empire Limited (SHMY, Nevada-incorporated shell company with ~$2K assets) agreed to acquire 100% of Meluha Therapeutics Berhad (Malaysian biotech, ~$2.2K assets) by issuing 10,000,000 shares of Series A Preferred Stock at $0.2155/share ($2,155,000 aggregate). The acquisition closed March 28, 2025. Meluha shareholders (Ramesh A/L Saravanamuthu 33.6%, Abdul Jalil bin Jidon 31.9%) received preferred shares and will control 56.8% combined voting power post-close. This is a reverse recapitalization; Meluha is the accounting acquirer. Meluha manufactures cell-based therapeutics (myCell, Chondrogen) targeting osteoarthritis in Malaysia; FY2024 revenue $1.006M, net income $667K; 9M FY2025 revenue $1.253M, net income $194K. Going concern doubt noted due to $1.9M accumulated deficit and negative working capital.
Why this rating
Major event: reverse merger brings operating biotech into shell; $2.2M company acquiring $2K shell is transformational for acquirer; $2.2M acquisition value vs. $2.2M combined assets is material. Not 75+ due to modest absolute scale and Malaysia-only operations.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.